DataMeds AI (MEDS) shares ripped higher on Wednesday morning as the company completed its acquisition of Helomics AI cancer diagnostics laboratory and precision oncology contract research organization (CEO). As investors reacted to MEDS' transformative deal, the AI stock soared past all of its key moving averages (MAs), accelerating the upward momentum on September 16.